Early this morning, GlaxoSmithKline (GSK $53.91) reported negative top-line results from its Phase III MARGIT trial with the MAGE-A3 vaccine…
Browsing: diseases
After the markets closed on Thursday, KaloBios reported fourth-quarter financial results and an update of clinical programs. While the financial…
Before the markets opened on Monday, Alexion announced the outcome of the reimbursement negotiations with the French government and consequently…
Dynavax ended the fourth quarter with $189.4 million in cash, which, according to our model, should sustain operations into 2016.…
Dynavax ended the fourth quarter with $189.4 million in cash, which, according to our model, should sustain operations into 2016.…